70 / 1851
The traditional drug development paradigm
Phase I
Phase II
Phase III
Safety
Efficacy in
selected
tumors
Meaningful benefit in
a randomized setting
against
existing
standard
Tolerability
ORR
OS
Pharmacokinetics
TTP
Pharmacodynamics PFS
Preliminary
antitumor activity